21
Jul
In a strong-worded reaction to the Drugs Controller General of India (DCGI)'s move to pull up drug major Glenmark on charges of alleged overpricing, false and misleading claims related to its COVID-19 drug Favipiravir, the company has responded to the apex drug controller saying it was "dismayed" over the careless, unsubstantiated allegations that are devoid of merits. In a letter to DCGI V.G. Somani, Glenmark said compared to other therapies approved for emergency use in COVID-19 in India, FabiFlu is much more economical and an effective treatment option. The estimated total cost of therapy for full course is only Rs 9,150, when compared to the prices of Remdesivir (Rs…